“ozanimod” Archives

in
Entry Author Date Location
Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More 06/05/20 National
BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info 05/13/20 New York
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More 03/27/20 National
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch 03/26/20 New York
Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More 06/07/19 National
Thwarting Opposition, Bristol Gets Shareholder OK for $74B Celgene Buyout 04/12/19 New York
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More 03/29/19 National
Amid Acquisition Drama, Celgene Resubmits MS Drug for FDA Approval 03/25/19 New York
Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More 03/15/19 National
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track 03/11/19 New York
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B 01/03/19 National
Bio Roundup: Not-BIO Party Foul, CRISPR Drama, Sickle Cell Updates 06/15/18 National
Arena Pharma’s Revamp Gains Traction With New Data For GI Drug 03/20/18 San Diego
Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More 03/02/18 National
FDA Refuses to Review Celgene’s MS Drug, Says File “Insufficient” 02/27/18 New York
Celgene’s Data Could Lead To New Option For Multiple Sclerosis Patients 05/22/17 New York
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
Celgene Touts Data From Early Study of Oral GI Drug 09/12/16 Boston
East Coast Biotech Roundup: Celgene, Chiasma, Cerulean, & More 07/17/15 Boston
Page 1 of 1